Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Did the World Just Gain Hundreds of Millions of Alzheimer's Patients? A new definition of Alzheimer's includes people without symptoms. Experts are fiercely divided over whether that makes sense--and whether the new drugs really help. Many have heralded a golden age of Alzheimer's research, excited by the promise of new amyloid-targeting antibodies. Yet a large meta-study of such antibodies concluded that they probably result in "little to no difference" in the decline of memory and of cognitive ability. This July, some ten thousand people descended on London for the Alzheimer's Association International Conference. Another three thousand of us joined virtually. I'm an anthropologist, accustomed to conferences where croissants at coffee breaks count as a luxury. This one opened with six trumpeters dressed as Buckingham Palace guards, followed by dancers who discoed, vogued, and high-kicked through the history of British pop. After the first day's sessions, participants dispersed to parties; at one, singers in sequins belted out covers while someone played an illuminated, transparent violin. One night, the London Eye was lit purple to honor the people in attendance. The mood matched the spectacle. Joanne Pike, the Alzheimer's Association's president and C.E.O., announced that recent advances had brought the campaign against the disease to a "pivotal moment." Maria Carrillo, its chief science officer, hailed a groundswell of progress. That optimism followed decades of disappointment. Between 1974 and 2020, the U.S. government spent roughly twenty billion dollars on Alzheimer's research without seeing the approval of a single treatment designed to act on the disease's underlying biology, let alone stop or reverse its course. Today, Alzheimer's afflicts roughly one in nine Americans over sixty-five and, along with related dementias, has been estimated to cost the economy about three-quarters of a trillion dollars a year. In surveys, it ranks with cancer as the disease people fear most. It typically starts by robbing patients of recent memories--conversations they just had, where they put important objects--before corroding the basic functions of adult independence, from paying bills to managing medications. Eventually, it leaves patients unable to speak, move, swallow, or recognize close relatives.

This material may not be published, broadcast, rewritten, or redistributed. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset . Powered and implemented by FactSet Digital Solutions . Mutual Fund and ETF data provided by LSEG . Identity thieves don't need your password anymore; here are 6 new account takeover threats Fox News AI Newsletter: Don't want AI on your phone? Is that campaign merch store official?

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

For heart disease, early diagnosis is vital for saving lives. For heart disease, early diagnosis is vital for saving lives. Doctors have developed a "superhuman" AI tool that can spot heart disease in less than two seconds. The groundbreaking technology has been trained on millions of patients and works by extracting more information from a routine electrocardiogram (ECG) than the human eye can typically see. The traditional ECG, which records electrical activity in the heart, including the rate and rhythm, has been a vital medical tool in diagnosing heart attacks and abnormal heart rhythms for a century.

This actor was told he had Alzheimer's, now he's performing a one-man show Image caption, Peter Marinker, who was diagnosed with Alzheimer's disease two years ago, began dress rehearsals for the Beckett play Krapp's Last Tape in June For four days running, Peter Marinker had arrived at rehearsals that were not even taking place. Dementia had muddled the dates in his mind. Yet he is now preparing to do something most actors would find daunting even with perfect recall: performing a much-loved Samuel Beckett play alone on a London stage. Marinker, 85, is best known for his voice work: from radio plays and video games to big-budget films like Labyrinth and Paddington in Peru. On camera he was the adviser to the US president in Love Actually and one of the airline passengers in the drama United 93.

Asbestos killed my mum in her 40s - was her school to blame? To play this video you need to enable JavaScript in your browser. Figure caption, 'Mum died young from asbestos - now my family want justice' When Caroline Bryan was enjoying high school with friends in the early 90s, she would never have imagined replaying those memories in her final weeks, while searching for answers about her terminal condition. The mum was 46 when she died from mesothelioma, an incurable cancer linked to asbestos exposure. As she came to terms with her difficult diagnosis, Caroline's belief was the only place she could have encountered asbestos was during her time at school decades earlier.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Recent advances in computational pathology have led to the emergence of numerous foundation models. These models typically rely on general-purpose encoders with multi-instance learning for whole slide image (WSI) classification or apply multimodal approaches to generate reports directly from images. However, these models cannot emulate the diagnostic approach of pathologists, who systematically examine slides at low magnification to obtain an overview before progressively zooming in on suspicious regions to formulate comprehensive diagnoses.

Foundation models trained on large-scale de-identified electronic health records (EHRs) hold promise for clinical applications. However, their capacity to memorize patient information raises important privacy concerns. In this work, we introduce a suite of black-box evaluation tests to assess privacy-related memorization risks in foundation models trained on structured EHR data. Our framework includes methods for probing memorization at both the embedding and generative levels, and aims to distinguish between model generalization and harmful memorization in clinically relevant settings. We contextualize memorization in terms of its potential to compromise patient privacy, particularly for vulnerable subgroups.